Literature DB >> 35276326

The Risk of Hepatocellular Carcinoma in Entecavir Versus Tenofovir Treated US Cohort With Chronic Hepatitis B Virus.

Jennifer R Kramer1, Peter A Richardson1, Hyunseok Kim2, Yao-Chun Hsu3, Fasiha Kanwal4, Hashem B El-Serag5.   

Abstract

The comparative effectiveness of tenofovir (TDF) vs entecavir (ETV) in reducing the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV) remains unclear. Data from a retrospective Korean cohort study published by Choi et al1 initially suggested a lower-than-expected incidence of HCC in patients on long-term TDF. However, additional studies from Korea did not show a statistically significant difference in HCC incidence rate between TDF and ETV groups,2,3 and subsequent studies reported mixed results ranging from no association or a slight advantage for TDF.4 Most of these studies examined Asian patients from Korea, Taiwan, and China.
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2022        PMID： 35276326      PMCID： PMC9452600          DOI： 10.1016/j.cgh.2022.02.056

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   13.576


  8 in total

1.  Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

Authors:  R B D'Agostino
Journal:  Stat Med       Date:  1998-10-15       Impact factor: 2.373

2.  Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.

Authors:  Jonggi Choi; Hyo Jeong Kim; Jayoun Lee; Songhee Cho; Min Jung Ko; Young-Suk Lim
Journal:  JAMA Oncol       Date:  2019-01-01       Impact factor: 31.777

3.  Noninvasive Tests for Fibrosis Predict 5-Year Mortality and Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.

Authors:  Jeong Han Kim; Ji Wan Kim; Jung Woong Seo; Won Hyeok Choe; So Young Kwon
Journal:  J Clin Gastroenterol       Date:  2016 Nov/Dec       Impact factor: 3.062

4.  A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.

Authors:  Seung Up Kim; Yeon Seok Seo; Han Ah Lee; Mi Na Kim; Yu Rim Lee; Hye Won Lee; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Seong Gyu Hwang; Kyu Sung Rim; Soon Ho Um; Won Young Tak; Young Oh Kweon; Beom Kyung Kim; Soo Young Park
Journal:  J Hepatol       Date:  2019-04-06       Impact factor: 25.083

5.  No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir.

Authors:  Feng Su; Kristin Berry; George N Ioannou
Journal:  Gut       Date:  2020-03-30       Impact factor: 23.059

Review 6.  Comparison of Propensity Score Methods and Covariate Adjustment: Evaluation in 4 Cardiovascular Studies.

Authors:  Markus C Elze; John Gregson; Usman Baber; Elizabeth Williamson; Samantha Sartori; Roxana Mehran; Melissa Nichols; Gregg W Stone; Stuart J Pocock
Journal:  J Am Coll Cardiol       Date:  2017-01-24       Impact factor: 24.094

7.  No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis.

Authors:  Jie Yuan; Yang Peng; Fa-Bao Hao; Ya-Qin Wang; Chun-Rui Wang; Guo-Chao Zhong
Journal:  Aging (Albany NY)       Date:  2021-02-26       Impact factor: 5.682

8.  Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.

Authors:  Sung Won Lee; Jung Hyun Kwon; Hae Lim Lee; Sun Hong Yoo; Hee Chul Nam; Pil Soo Sung; Soon Woo Nam; Si Hyun Bae; Jong Young Choi; Seung Kew Yoon; Nam Ik Han; Jeong Won Jang
Journal:  Gut       Date:  2019-10-31       Impact factor: 23.059
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.